Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
FOSTER CITY, Calif., Feb. 15, 2017 -- PointCross Life Sciences came out of stealth mode with its Xbiom™ Insights solution for Clinical Biomarker research. With two clients deployed, PointCross is now acquiring new pharma and biotechnology companies who are pursuing precisely targeted therapies in oncology, central nervous system, and cardiovascular. Having proven the capability and value to researchers over the past year, the company has now formally launched its Xbiom™ big data platform.
“Semantically integrating four normally disconnected data sources – clinical data, biomarker data, bio-sample availability, and bioinformatics registry data – into a single point from where researchers can search, stratify cohorts, correlate and analyze clinical findings against biomarkers in minutes is a paradigm changing capability for both big pharma as well as smaller biotech companies,” says Dr. Suresh Madhavan, CEO at PointCross.
The Xbiom™ platform is built on a proven stack of big data technologies, including PointCross' underlying Orchestra® technology with a robust big data stack that is serving the pharmaceutical industry with its petabyte scale. This stack includes Hadoop HDFS, Spark, Cassandra, Lucene/SOLR, and Hive that support the Orchestra® ontology, collaboration, Role Based Access Control and Semantic Data Exchange engines. It is available for big pharma who need users and applications to access the data within Xbiom™. It is also available as a SaaS solution, suitable for smaller biotech firms.
The Xbiom™ platform serves the R&D and Regulatory needs in both non-clinical and clinical development lifecycle as well as biomarker R&D to support translational and precision medicine development. In addition to the Xbiom™ Insights-Clinical Biomarker solution, PointCross also offers Xbiom™ Insights-Nonclinical, Xbiom™ Regulatory-Clinical, and Xbiom™ Regulatory-Nonclinical solutions.
About PointCross Life Sciences
PointCross Life Sciences provides the life sciences industry with data management, analytics and visualization solutions that reduce risks, improve data quality, shorten time to market, and generate better insights from R&D and regulatory data. We are a strategic solution provider to the FDA and to several major Biopharma companies. PointCross was recognized in 2013 as one of Gartner’s Cool Vendors in Life Sciences.
Press Contact: Kunaal Madhavan, Marketing at PointCross Life Sciences www.pointcrosslifesciences.com [email protected]
